Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage biopharmaceutical company focused on oncology, announced its participation in the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The event will take place in New York City on May 20, 2024, with a fireside chat scheduled for 11:30 AM ET. A webcast of the chat will be available live and archived for 90 days on the company's events page. Compass Therapeutics specializes in developing antibody-based therapeutics aimed at treating various human diseases.
- Compass Therapeutics is actively engaging in investor conferences, which can enhance visibility and investor confidence.
- The archived webcast provides accessibility for investors who cannot attend the live event, potentially broadening the audience.
- No new financial or clinical data were presented, which might leave investors wanting more substantial updates.
- Participation in conferences may not directly influence stock performance without accompanying significant company achievements or data releases.
BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference taking place in New York City, NY on May 20, 2024.
Fireside Chat details
Date: Monday, May 20
Time: 11:30 AM ET
Webcast Link: https://journey.ct.events/view/
Virtual/Replay availability: The corporate presentation will be archived for 90 days on Compass’ Events page.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.
Investor Contact
ir@compasstherapeutics.com
Media Contact
Anna Gifford, Senior Communications Manager
media@compasstherapeutics.com
617-500-8099
FAQ
What is the date and time of Compass Therapeutics' participation in the H.C. Wainwright 2nd Annual BioConnect Investor Conference?
How can I watch the Compass Therapeutics fireside chat from the H.C. Wainwright 2nd Annual BioConnect Investor Conference?
What type of therapeutics does Compass Therapeutics develop?
Where will the H.C. Wainwright 2nd Annual BioConnect Investor Conference be held?
What is Compass Therapeutics' stock symbol?
